News
JAZZ
242.76
+3.41%
8.00
Don't Overlook Jazz (JAZZ) International Revenue Trends While Assessing the Stock
NASDAQ · 8h ago
What Jazz Pharmaceuticals Holders Bought Into
Simply Wall St · 9h ago
Weekly Report: what happened at JAZZ last week (1102-1106)?
Weekly Report · 11h ago
Is Jazz Pharmaceuticals (JAZZ) Undervalued On Raised 2026 Guidance And Ziihera Data?
Simply Wall St · 4d ago
Jazz Advances Early JZP269 Study as Investors Await Safety Data
TipRanks · 5d ago
Jazz Pharmaceuticals (JAZZ) Stock Jumps After Q3 Results Despite EPS Loss
Simply Wall St · 5d ago
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
PR Newswire · 6d ago
Jazz Pharmaceuticals (JAZZ) Sets Revenue Record As Pipeline News Reshapes The Story
Simply Wall St · 6d ago
Jazz Pharmaceuticals Price Target Raised to $310.00/Share From $300.00 by JP Morgan
Dow Jones · 6d ago
Jazz Pharmaceuticals Is Maintained at Overweight by JP Morgan
Dow Jones · 6d ago
JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $310
Benzinga · 6d ago
Jazz Pharmaceuticals Is Maintained at Overweight by Morgan Stanley
Dow Jones · 6d ago
Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $319
Benzinga · 6d ago
Jazz climbs as 2026 revenue guidance boosted
Seeking Alpha · 6d ago
Jazz’s Epidyolex Follow-Up Study Reaches Completion: What It Means for JAZZ Investors
TipRanks · 6d ago
Jazz Pharmaceuticals Is Maintained at Outperform by RBC Capital
Dow Jones · 6d ago
Jazz Pharmaceuticals Price Target Raised to $305.00/Share From $296.00 by RBC Capital
Dow Jones · 6d ago
RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $305
Benzinga · 6d ago
Jazz Pharmaceuticals Is Maintained at Overweight by Barclays
Dow Jones · 6d ago
Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $275
Benzinga · 6d ago
More
Webull provides a variety of real-time JAZZ stock news. You can receive the latest news about Jazz Pharmaceuticals Plc through multiple platforms. This information may help you make smarter investment decisions.
About JAZZ
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, ABS-1230, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.